4-OHA, a potent and selective inhibitor of estrogen biosynthesis, will be synthesized for use in the following studies. Evaluation of the effect of 4-OHA in breast cancer patients are proposed. In previous studies, 29% of patients responding to 4-OHA had not respond to previous antiestrogen treatment (tamoxifen) while a further 50% had relapsed for prior endocrine therapy. The significance of tumor aromatase to tumor growth will be determined by using the sensitive immunocytochemical peroxidase-antiperoxidase (PAP) technique with recently prepared polyclonal antibodies to aromatase. Antibodies to estrogen and progesterone receptors will be applied to the same tissue preparation for comparison. Concentrations of estrone, estradiol, estrone sulfate and androgen precursors will be measured in the tumor samples. The influences of c-ras/H oncogenic protein on hormone-dependent and hormone independent tumor growth will also be investigated by the above technique. The expression of the oncogenic protein (p21) will be determined in tumor samples from patients before and during treatment with aromatase inhibitor. Similar in vitro studies to the above will be carried out in tissue from patients with benign prostatic hypertrophy and prostatic cancer. Prostatic tissues will also be grown in nude mice and the effect of 4-OHA on the tumors determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA027440-11
Application #
3167640
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1981-09-30
Project End
1992-06-30
Budget Start
1989-07-27
Budget End
1990-06-30
Support Year
11
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Njar, Vincent C O; Brodie, Angela M H (2015) Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem 58:2077-87
Bruno, Robert D; Vasaitis, Tadas S; Gediya, Lalji K et al. (2011) Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 76:1268-79
Burks, Scott R; Macedo, Luciana F; Barth, Eugene D et al. (2010) Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells. Breast Cancer Res Treat 124:121-31
Schayowitz, A; Sabnis, G; Goloubeva, O et al. (2010) Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 103:1001-7
Brodie, Angela; Njar, Vincent; Macedo, Luciana Furtado et al. (2009) The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol 27:53-63
Vasaitis, Tadas; Belosay, Aashvini; Schayowitz, Adam et al. (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7:2348-57
Bruno, Robert D; Gover, Tony D; Burger, Angelika M et al. (2008) 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther 7:2828-36
Tang, Yao; Khan, Mohammad A; Goloubeva, Olga et al. (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12:169-74